ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening for Age-Related Skeletal Muscle Dysfunction (ARMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02277236
Recruitment Status : Active, not recruiting
First Posted : October 28, 2014
Last Update Posted : May 12, 2017
Sponsor:
Information provided by (Responsible Party):
Michael Harris-Love, Washington D.C. Veterans Affairs Medical Center

Brief Summary:
This pilot study will aid the development of a sonographic screening method used to obtain proxy measures of LBM and estimates of muscle composition that relate to Intramuscular adipose tissue (IMAT), lipid metabolism, and insulin resistance. Typically, age-related muscle loss is not assessed in older adults until they began to show signs of trouble managing their own lives independently. In addition to the loss of independence that is typically seen with diminished muscle mass and function (sarcopenia), age-related changes in lean body mass can have negative effects on insulin sensitivity. The investigators central hypothesis is that the muscle characteristics derived from ultrasound (US) will be significantly associated with estimates of dual energy X-ray absorptiometry (DXA) LBM, CT scan measures of IMAT, estimates of insulin homeostasis, and serum levels of inflammatory cytokines.

Condition or disease Intervention/treatment
Sarcopenia Radiation: DXA scanning Radiation: CT imaging

Detailed Description:

The primary goals of this project are to: 1) develop and validate a rapid, portable, cost-effective, screening method for sarcopenia using diagnostic ultrasound (US), and 2) determine if the US screening method provides viable estimates of intramuscular adipose tissue (IMAT) since muscle tissue age-related changes in muscle composition are associated with low muscle torque and metabolic dysfunction. The proposed US screening method may be used as a proxy measure of LBM and provide estimates of skeletal muscle composition that relate to IMAT, lipid metabolism, insulin homeostasis and inflammation - important factors that may impact impaired mobility and metabolic dysfunction in older African American Veterans.

Aim 1:

Determine the association between a proxy measure of LBM obtained via portable, diagnostic, musculoskeletal US and LBM as determined by dual energy X-ray absorptiometry (DXA).

The working hypothesis is that a 6-muscle model of LBM derived from US and DXA LBM values will exhibit a significant positive association and attain a coefficient of determination > .80.

Aim 2:

Determine the association between US echointensity features and IMAT as determined by CT scan.

US echointensity values will be acquired from the rectus femoris and analyzed to determine the association with IMAT. The working hypothesis is that higher echointensity values measured with grayscale analysis will be negatively associated with the Hounsfield units obtained from the CT scan (p < .05).

Aim 3:

Examine the association between US echointensity values and biologic factors that impair insulin sensitivity.

Excessive IMAT and intra-myocellular triglyceride levels result in increased levels of biologic factors such as inflammatory cytokines (TNF-α and IL-6), which may affect insulin sensitivity. The investigators hypothesis is that proxy measures of IMAT via echointensity values will be positively associated with biomarkers of inflammation and insulin homeostasis.


Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Creating a Model of Proactive Geriatric Care Within VISN 5: Screening for Age-Related Skeletal Muscle Dysfunction at the Washington DC VA Medical Center
Study Start Date : October 2014
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans
U.S. FDA Resources

Group/Cohort Intervention/treatment
Younger Veterans
Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
Radiation: DXA scanning
Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Other Name: Radiograph, x-rays
Radiation: CT imaging
Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Other Name: CAT scan
Young-Old Veterans
Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
Radiation: DXA scanning
Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Other Name: Radiograph, x-rays
Radiation: CT imaging
Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Other Name: CAT scan



Primary Outcome Measures :
  1. Sonographic Lean Body Mass [ Time Frame: 1 day ]
    US estimates of aggregate regional LBM (muscle thickness, cm), will be assessed using B-mode diagnostic US with a 13-6 MHz linear array transducer for morphology measures at 6 axial and appendicular sites. The following sites will be assessed: the midpoint of the upper trapezius, upper pectoralis major, lateral deltoid, brachioradialis, rectus femoris, and tibialis anterior.


Secondary Outcome Measures :
  1. Metabolic status [ Time Frame: 1 day ]
    A blood sample (60 cc) will be obtained after an 8-hour overnight fast: glucose and insulin levels will be assessed before and during a standard (75 g) 2 hour oral glucose tolerance test. Other laboratory values such as a standard lipid profile and selected cytokines (IL-6), will also be measured.

  2. DXA lean body mass [ Time Frame: At time of assessment ]
    Participants will undergo dual energy X-ray absorptiometry (DXA) scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total LBM, and body fat percentage (BF%).

  3. Intramuscular adipose tissue assessment [ Time Frame: 1 day ]
    Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. A single, unilateral 10mm axial image slice (120 kVp, 200 to 250 mA) of the thigh will be obtained at the midfemur region (corresponding to the ultrasound scanning site).

  4. Strength assessment [ Time Frame: 1 day ]
    Grip strength will be assessed bilaterally; isokinetic knee extension/flexion torques will be obtained bilaterally using the Biodex System 4. Peak concentric torque (at 60º/s and 180º/s) will be obtained in a randomized fashion with subject positioning and stabilization per the Biodex Operations Manual.

  5. Functional assessment [ Time Frame: 1 day ]
    A standardized timed sit-to-stand test will be conducted (5 repetitions); 6m walking speed (habitual and fast gait) will be recorded; the Physical Performance Test (PPT-7), a functional battery validated for use with older adults, will be used in this study to assess the activities of daily living of the participants.

  6. Physical activity questionnaire [ Time Frame: 1 day ]
    Participants will also complete the International Physical Activity Questionnaire (IPAQ) to obtain an estimate of their customary activity and formal exercise.


Biospecimen Retention:   Samples Without DNA
Blood samples will be collected for determination of lipid profiles, fasting insulin and glucose levels, the oral glucose tolerance test, and selected cytokines (IL-6 and TNF-α).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Veteran men (45-85 years of age; n = 30) consecutively recruited from outpatients at the DC VAMC and assigned to a "younger" or "young old" group (i.e., 45-64.9, and 65-84.9 years of age).
Criteria

Inclusion Criteria: You are eligible to participate if:

  1. You are registered to receive healthcare at the Washington DC VAMC through the Geriatrics Extended Care Service and/or Primary Care Service.
  2. You are a male.
  3. You are between the ages of 45 - 85 years.
  4. Must be able to stand comfortably for 10 minutes and walk a short distance (use of assistive devices are acceptable).

Exclusion Criteria: You are not eligible to participate if:

  1. You have uncontrolled hypertension.
  2. Body Mass Index (BMI) <18.5 or >32.5.
  3. Musculoskeletal conditions that would stop you from performing the physical assessment test.
  4. Muscle weakness due to neurological disease or injury (such as stroke or spinal cord injury).
  5. Moderate to severe sepsis (blood infection) or edema (such as swelling of a limb).
  6. Currently prescribed medications that affect glucose or insulin.
  7. Uncontrolled cardiovascular disease.
  8. Hospitalization over the last three months.
  9. Diagnosis of diabetes.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02277236


Locations
United States, District of Columbia
Washington DC VA Medical Center
Washington, D.C., District of Columbia, United States, 20422
Sponsors and Collaborators
Washington D.C. Veterans Affairs Medical Center
Investigators
Principal Investigator: Michael Harris-Love, MPT, DSc Washington DC VA Medical Center

Publications:
Responsible Party: Michael Harris-Love, Principal Investigator, Washington D.C. Veterans Affairs Medical Center
ClinicalTrials.gov Identifier: NCT02277236     History of Changes
Other Study ID Numbers: MIRB01671
First Posted: October 28, 2014    Key Record Dates
Last Update Posted: May 12, 2017
Last Verified: May 2017

Keywords provided by Michael Harris-Love, Washington D.C. Veterans Affairs Medical Center:
sarcopenia
aging
insulin resistance
screening

Additional relevant MeSH terms:
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical
Signs and Symptoms